MedTrace Logo

Alpha-galactosidase Enzyme and Irritable Bowel Syndrome

NCT01243853 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2011-01-17

No results posted yet for this study

Summary

The purpose of this study is to determine whether alpha-galactosidase enzyme is affective in alleviating the symptoms of irritable bowel syndrome (IBS).

Conditions

  • Irritable Bowel Syndrome

Interventions

DIETARY_SUPPLEMENT

Alpha-galactosidase

3 months intervention, daily 3 x 3 capsules alpha-galactosidase enzyme (400 GalU/capsule) or 3 x 3 capsules placebo

Sponsors & Collaborators

  • Verman Oy Ab

    lead INDUSTRY

Principal Investigators

  • Jari Koskenpato, MD, PhD · Gastrolääkärit Oy

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-12-31
Completion
2012-02-29

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01243853 on ClinicalTrials.gov